Scarica l'app Stockscreener
15.66
0.63%
-0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$15.76
Aprire:
$15.71
Volume 24 ore:
245.55K
Relative Volume:
0.54
Capitalizzazione di mercato:
$636.04M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-3.0526
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
+0.45%
1M Prestazione:
+14.22%
6M Prestazione:
+33.16%
1 anno Prestazione:
-72.23%
Intervallo 1D:
$15.51
$15.84
Intervallo di 1 settimana:
$15.23
$15.85
Portata 52W:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.66 | 635.63M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Parkman Healthcare Partners LLC Has $2.22 Million Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Invesco Ltd. Purchases 20,650 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Aug Retail: Is Keros Therapeutics Inc. still a buy after recent gainsJuly 2025 Weekly Recap & AI Driven Price Predictions - Lancaster City Council
Can AC Immune SA weather a recessionForecast Cut & High Yield Stock Recommendations - Lancaster City Council
Keros Therapeutics, Inc. $KROS Shares Sold by Russell Investments Group Ltd. - MarketBeat
Keros Therapeutics reports positive data for DMD drug candidate By Investing.com - Investing.com South Africa
Sector Leaders Rotate Capital Into Keros Therapeutics Inc.Weekly Volume Report & Community Driven Trade Alerts - beatles.ru
Published on: 2025-09-08 19:14:17 - beatles.ru
Keros Therapeutics reports positive data for DMD drug candidate - Investing.com
Keros Therapeutics Presents Promising Phase 1 Trial Data - TipRanks
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - GlobeNewswire
Sustained Bone Density Gains: Keros' KER-065 Shows Promise in Phase 1 DMD Treatment Trial Results - Stock Titan
Keros Therapeutics, Inc. $KROS Shares Sold by Alkeon Capital Management LLC - MarketBeat
Can Keros Therapeutics Inc. reach all time highs this yearMarket Risk Summary & Safe Entry Point Identification - beatles.ru
Keros Therapeutics, Inc. $KROS is ADAR1 Capital Management LLC's 8th Largest Position - MarketBeat
PDT Partners LLC Purchases Shares of 276,060 Keros Therapeutics, Inc. $KROS - MarketBeat
What institutional flow reveals about Keros Therapeutics Inc.Portfolio Value Report & Daily Stock Momentum Reports - Newser
What MACD and RSI say about Keros Therapeutics Inc.Weekly Risk Summary & AI Optimized Trading Strategy Guides - Newser
Real time alert setup for Keros Therapeutics Inc. performance2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Keros Therapeutics Inc. stock outlook for YEARWeekly Risk Summary & AI Powered Market Trend Analysis - Newser
464,895 Shares in Keros Therapeutics, Inc. $KROS Purchased by DRW Securities LLC - MarketBeat
Will Keros Therapeutics Inc. benefit from green energy policiesJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - خودرو بانک
Is Keros Therapeutics Inc. backed by strong institutional buyingDollar Strength & Real-Time Sentiment Analysis - خودرو بانک
Can Keros Therapeutics Inc. lead its sector in growthEarnings Recap Report & Daily Profit Focused Stock Screening - خودرو بانک
What candlestick patterns are forming on Keros Therapeutics Inc.July 2025 Selloffs & Verified Momentum Stock Ideas - Newser
Short interest data insights for Keros Therapeutics Inc.Market Sentiment Report & AI Forecast Swing Trade Picks - Newser
Keros Therapeutics Inc. stock trend forecastCPI Data & Fast Gaining Stock Strategy Reports - Newser
How to build a dashboard for Keros Therapeutics Inc. stock2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Can Keros Therapeutics Inc. hit a new high this monthJuly 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Is this a good reentry point in Keros Therapeutics Inc.Weekly Stock Report & Daily Oversold Bounce Ideas - Newser
Exit strategy if you’re trapped in Keros Therapeutics Inc.Jobs Report & Weekly Consistent Profit Watchlists - Newser
Is Keros Therapeutics Inc. forming a breakout patternWeekly Trade Analysis & Weekly High Return Forecasts - خودرو بانک
103,826 Shares in Keros Therapeutics, Inc. $KROS Acquired by Jump Financial LLC - MarketBeat
Charles Schwab Investment Management Inc. Sells 37,759 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Real time social sentiment graph for Keros Therapeutics Inc.2025 Price Targets & Real-Time Price Movement Reports - Newser
Walleye Capital LLC Sells 47,163 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Inc. stock chart pattern explained2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - Newser
Intraday pattern recognizer results for Keros Therapeutics Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Pattern recognition hints at Keros Therapeutics Inc. upside2025 Geopolitical Influence & AI Driven Price Predictions - Newser
Published on: 2025-09-03 23:43:48 - Newser
Analyzing Keros Therapeutics Inc. with risk reward ratio chartsWeekly Trade Recap & Verified Momentum Watchlists - Newser
Is it time to cut losses on Keros Therapeutics Inc.Trade Risk Summary & Long-Term Safe Investment Plans - Newser
Statistical indicators supporting Keros Therapeutics Inc.’s strengthPortfolio Risk Summary & Comprehensive Market Scan Reports - Newser
Applying chart zones and confluence areas to Keros Therapeutics Inc.IPO Watch & Safe Capital Growth Trade Ideas - Newser
Does Keros Therapeutics Inc. qualify in momentum factor screening2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Apr 09 '25 |
Buy |
10.13 |
934,258 |
9,464,512 |
4,392,737 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):